3950 – Pancreatitis GP2

Highlights

• Use of monoclonal antibodies against GP2
• Ready-to-use (exception: wash buffer), color- and barcoded reagents
• Quality assured handling in routine laboratories
• Short incubation times (60 min / 30 min / 15 min) at room temperature
• Quantitative determination of glycoprotein 2 isoform alpha (GP2a) in ng/mL
• Excellent diagnostic sensitivity and specificity shortly after onset of the disease
• Correlation with the acuity of pancreatitis
• High precision and linearity within the measurement range
• CE marked
• Fully automatable

Intended Purpose

The Pancreatitis GP2 is a quantitative immunoassay for the determination of glycoprotein 2 isoform alpha (GP2a) in human serum. The Pancreatitis GP2 is intended as an aid in the diagnosis of acute pancreatitis in conjunction with other clinical and laboratory findings. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

Acute pancreatitis is a gastrointestinal, inflammatory disease of the pancreas, which manifests by severe abdominal pain, nausea, vomiting, constipation and fever. Generally, the patients recover completely, but a range of complications may occur, that can take life-threatening courses. The incidence of acute pancreatitis is about 20-70 cases per 100,000 inhabitants per year.

Researchers have not yet fully elucidated the pathophysiology of acute pancreatitis, but they consider that premature intra-pancreatic activation of digestive enzymes such as trypsin, lipases, or phospholipases causes autodigestion and triggers inflammation of the organ. Thus, acute pancreatitis begins with the destruction of the acinar cells of the pancreas, resulting in a basolateral release of a number of proteins of the zymogen granules.

Glycoprotein 2 (GP2) as a Diagnostic Marker

Recently, researchers detected elevated serum concentrations of glycoprotein 2 (GP2), a major component of the membrane of zymogenic granules, in a well-characterized animal model of acute pancreatitis. Based on this model, they developed an ELISA to measure pancreatitis-specific GP2 and investigated the diagnostic and prognostic value of GP2 concentrations in serum samples from patients with acute pancreatitis. The comprehensive study confirmed the isoform alpha of glycoprotein 2 (GP2a) as a specific serological marker of acute pancreatitis. In addition, glycoprotein 2 isoform alpha (GP2a) is considered a prognostic marker for severe, sometimes fatal disease progression and can be used to differentiate acute from chronic pancreatitis.

Publications

• Frost et al., (2024) Fecal glycoprotein 2 is a marker of gut microbiota dysbiosis and systemic inflammation
• Lopens et al., (2024) Antimicrobial GP2 in gallstones, bile fluid and peribiliary glands of patients with PSC
• Roggenbuck et al., (2017) Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum GP2